Open isolators let you reach in and out, but closed isolators are completely sealed — materials enter and exit through pass‑through chambers. The US pharmaceutical isolator market research shows that closed isolators are the fastest‑growing type, with a CAGR above 11%. Why? Because of potent compounds (ADCs, oligonucleotides) that are toxic even in tiny amounts. A leak could kill the operator.

What's driving adoption? The rise of cell and gene therapy. CAR‑T cells are made from a patient's own immune cells — any contamination destroys the batch. The US pharmaceutical isolator market trends highlight that biopharma companies are the largest end‑user segment, but CROs/CMOs are the fastest‑growing — because they make drugs for many clients and need flexible isolator systems.

But closed isolators are expensive — $500k‑$2M per unit. And they require rigorous validation and maintenance. That's why some smaller companies still use open isolators or even biosafety cabinets (which are cheaper but less safe).

The takeaway: if you're handling potent compounds, don't skimp on containment. Closed isolators are the gold standard. Your employees' health depends on it.